MethylGene Inc.

MethylGene Inc.

November 01, 2005 10:00 ET

MethylGene to Present at Rodman & Renshaw Techvest 7th Annual Healthcare Conference

MONTREAL, CANADA--(CCNMatthews - Nov. 1, 2005) - MethylGene Inc. (TSX:MYG) today announced that Donald F. Corcoran, President and Chief Executive Officer of MethylGene, will present at the Rodman & Renshaw Techvest 7th Annual Healthcare Conference in New York City at 11:35 a.m., ET on Tuesday, November 8, 2005.

An audio webcast of Mr. Corcoran's remarks will be available live. You can access the webcast at: An archived version of the remarks will also be available through the Company's web site for a limited time following the conference.

About MethylGene

MethylGene is a publicly traded biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics in cancer and infectious disease. Two cancer product candidates are currently in clinical trials: MGCD0103, partnered with Taiho Pharmaceutical for certain Asian countries, and MG98, partnered with MGI Pharma for North America.

MGCD0103 is currently in Phase I dose-escalation monotherapy trials against solid tumours and hematological malignancies. MG98 has entered a randomized two-step Phase II combination trial with interferon alpha in metastatic renal cell cancer. MethylGene has an exclusive license agreement with Merck & Co. for the development and commercialization of small molecule beta-lactamase inhibitors to overcome antibiotic resistance. MethylGene has a portfolio of preclinical programs for its multi-targeted kinase and histone deacetylase (HDAC) inhibitors for both oncology and non-oncology indications, and continues to seek partnering opportunities in these areas. Please visit MethylGene's website at

Contact Information

  • MethylGene Inc.
    Donald F. Corcoran
    President & CEO
    (514) 337-3333, ext.224
    (514) 337-0550 (FAX)
    MethylGene Inc.
    Andrea Gilpin
    Director, Investor Relations & Project Management
    (514) 337-3333, ext. 416
    (514) 337-0550 (FAX)